In a report released on July 30, Roanna Ruiz from Leerink Partners maintained a Hold rating on Amarin, with a price target of $10.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Roanna Ruiz has given her Hold rating due to a combination of factors affecting Amarin’s business outlook. The company’s strategic shift to partner with Recordati in Europe is a positive move, as it enhances operational flexibility and reduces costs, potentially leading to future royalty and milestone revenues. However, despite these improvements, the US market for Vascepa remains challenging due to intense competition from generic alternatives, which has resulted in a decline in US sales.
While Amarin has managed to maintain key exclusive contracts and even grow market share in the US, the overall pressure from generics continues to impact its performance. On the positive side, the Recordati partnership has significantly boosted European revenues and is expected to continue scaling. With a strong cash position and no debt, Amarin is positioned to pursue strategic initiatives, but the conservative outlook for the US market tempers the overall growth prospects, justifying the Hold rating.
In another report released yesterday, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $15.00 price target.